<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637663</url>
  </required_header>
  <id_info>
    <org_study_id>0740-67-5</org_study_id>
    <nct_id>NCT00637663</nct_id>
  </id_info>
  <brief_title>Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA</brief_title>
  <official_title>Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-labelled, prospective 96-week study comparing the antiviral
      efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining
      lamivudine 100mg QD treatment in CHB patients currently receiving lamivudine monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Entecavir has a higher potent antiviral efficacy and a lower drug resistance rate than those
      of Lamivudine in nucleoside-naïve CHB patients. The switch from Lamivudine to Entecavir in
      patients who have undetectable hepatitis B virus DNA (HBV DNA &lt; 60 IU/mL) may lead to more
      prolonged viral suppression to undetectable level by PCR method, compared to patients with
      continuous lamivudine treatment. The results of this study will provide a rationale for
      switch treatment from one antiviral to another one, especially from LAM to ETV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage number of patients with HBV DNA &lt; 60 IU/mL (Undetectable serum HBV DNA by PCR method) while on randomized therapy</measure>
    <time_frame>at Week 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage number of patients with HBV DNA &lt; 60 IU/mL (Undetectable serum HBV DNA by PCR method) while on randomized therapy</measure>
    <time_frame>at Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage number of patients who achieved ALT normalization, HBeAg loss, HBe seroconversion, HBsAg loss and HBs seroconversion</measure>
    <time_frame>at Week 48 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative discontinuation rates due to lamivudine or entecavir resistance mutations and clinical breakthrough, Safety assessment</measure>
    <time_frame>Follow up period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir 0.5 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lamivudine 100 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>entecavir 0.5 mg QD</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Baraclude 0.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>lamivudine 100 mg QD</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Zeffix 100mg QD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (18-70 years of age) currently taking lamivudine monotherapy for
             chronic HBV infection for at least 6 months with &lt; HBV DNA 60 IU/mL level and HBeAg
             positive status.

        Exclusion Criteria:

          -  Subjects treated with other antiviral drugs (e.g. adefovir) in combination with
             lamivudine are not eligible for this study.

          -  Subjects should have ALT ＜ 10 x ULN, and no evidence of hepatocellular carcinoma.

          -  Subjects should be without serological evidence of co-infection with HCV, HIV, or HDV.

          -  Subjects with decompensated liver disease, as well as pregnant or breast-feeding
             women, will not be eligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Heo, M.D. Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Pusan National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Hoon Ahn, M.D.Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei Univsersity College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Yong Park, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University School of Medicine</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

